Allergic rhinitis (AR), an inflammatory disease of the nasal membrane, is characterized by symptoms such as sneezing, rhinorrhea, nasal congestion, and nasal itching. AR is often associated with eye symptoms, such as tearing, redness, and itching, and is caused by sensitization to one or more aeroallergens. It is a common disorder worldwide; it may affect up to 40% of the general population. In Italy, its prevalence has steadily increased over the past decades in almost all age classes,^[@B1]^ and currently is estimated ∼25%.^[@B2]^ The diagnosis of AR is based on the demonstration of the production of allergen specific IgE (sIgE) and on the concordance between allergy testing and history, such as the symptom occurrence after inhalation of the sensitizing allergen.

AR was conventionally classified into seasonal AR and perennial AR based on the duration of exposure and symptoms.^[@B3]^ The common allergens for perennial AR include indoor allergens, such as house-dust mite, molds, and animal dander, whereas those allergens for seasonal AR are usually outdoor allergens, such as tree pollen, grass pollen, weed pollen, and molds.^[@B4]^ Some patients sensitized to seasonal allergens have symptoms throughout the year, and some patients sensitized to perennial allergens have symptoms during specific seasons. In addition, many patients are sensitized to both perennial allergens and seasonal allergens simultaneously. The conventional classification has some limitations from a therapeutic standpoint due to its poor association with clinical symptoms. In 2001, the World Health Organization proposed a new Allergic Rhinitis and its Impact on Asthma (ARIA) classification, which classifies AR according to severity and symptom duration.^[@B5]^

Skin-prick test (SPT) and sIgE measurements are the most common methods used to diagnose allergy. Both techniques are widely accepted diagnostic tools. Several researchers investigated the concordance between the level of sIgE and SPT.^[@B6]--[@B11]^ SPTs have been used for decades to prove or exclude sensitization to allergens. Also, sIgE assessment is popular and, particularly in patients who are polysensitized, allows defining the relevance of sensitizing allergens more appropriately than SPT in choosing the allergen extract for allergen immunotherapy.^[@B12]^ Previously, two studies reported that serum IgE levels were related to symptom severity in children with seasonal and perennial AR.^[@B7],[@B8]^ Therefore, this study aimed to relate the serum sIgE levels with symptom severity assessed by ARIA criteria in a group of adults with AR.

METHODS
=======

Two-hundred-and-seventeen patients (123 women, 94 men; median age, 39.5 years) were enrolled in the study. Inclusion criteria were (1) documented AR diagnosis, and (2) sensitization to house-dust mite to exclude significant seasonal interference on study evaluation. Blood sampling for assessing sIgE levels was performed in all the subjects. The review board of the Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo approved the procedure, and all the patients gave their written informed consent.

Serum levels of sIgE to house-dust mite were detected by the fluorescence enzyme immunoassay (ImmunoCAP; Thermo Fisher Scientific, Milan, Italy) in peripheral blood samples of the patients. The serum was separated from all the blood samples within 4 hours and stored at −20°C until allergen sIgE was evaluated against allergens. The allergen of interest, covalently coupled to ImmunoCAP, reacted with the sIgE in the patient sample. After washing away non-sIgE, enzyme-labeled antibodies against IgE were added to form a complex. After incubation, unbound enzyme--anti-IgE was washed away and the bound complex was then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate was measured. The higher the response was valued, the more sIgE was present in the specimen. To evaluate the test results, the response for the patient samples was transformed to concentrations with the use of a calibration curve. Quantitative sIgE concentrations were expressed in kU/L according to the traceable calibration to the second international reference preparation 75/502 of human serum IgE from the World Health Organization; sIgE levels were considered positive at \>0.35 kU/L. In the present study, the highest sIgE level was considered in each polysensitized patient.

According to the ARIA classification, AR was subdivided based on the duration and/or chronicity of symptoms (intermittent for symptoms \<4 days/wk or \<4 wk/y or persistent for symptoms \>4 days/wk and \>4 wk/y), and grading the symptom severity (mild when symptoms do not impair sleep, daily activities, and work and/or school performance; or moderate to severe when symptoms impair sleep, daily activities, and work and/or school performance).^[@B5]^

Statistical Analysis
--------------------

Statistical analysis was performed by using the statistical software package Medcalc 9 (Frank Schoonjans, Oostende, Belgium). Medians and percentiles (25th and 75th) (interquartile range \[IQR\]) were used as descriptive statistics. The nonparametric Wilcoxon test was used to compare the samples. The nonparametric Kruskal-Wallis rank test was performed to evaluate the analysis of variance between the patient groups. A *p* value of \<0.05 was considered statistically significant.

RESULTS
=======

Twenty-five patients had mild intermittent symptoms, 41 had moderate-to-severe intermittent symptoms, 61 had mild persistent symptoms, and 90 moderate-to-severe symptoms. The sIgE levels to aeroallergens in patients with AR significantly (*p* = 0.0032, Kruskal-Wallis test) changed with regard to ARIA classification, as shown in [Fig. 1](#F1){ref-type="fig"}. In particular, there was a significant difference of sIgE levels to house-dust mite between patients with mild intermittent symptoms (median, 6.91 kU/L; IQR, 1.46--24.28 kU/L) and those with mild persistent symptoms (median, 14.2 kU/L; IQR, 4.74--36.35 kU/L) (*p* = 0.0463, Wilcoxon test); mild intermittent symptoms and moderate-to-severe persistent symptoms (median, 30.7 kU/L; IQR, 6.69--101 kU/L) (*p* = 0.0005, Wilcoxon test); between patients with moderate-to-severe intermittent symptoms (median, 11.09 kU/L; IQR, 0.53--37.25 kU/L) and with moderate-to-severe persistent symptoms (*p* = 0.0022, Wilcoxon test); and patients with mild persistent symptoms and moderate-to-severe persistent symptoms (*p* = 0.0259, Wilcoxon test).

![The specific immunoglobulin E (sIgE) values (kU/L) to house-dust mite distribution in patients with allergic rhinitis (AR) and with allergy for aeroallergens cause of allergy, evaluated by using the Allergic Rhinitis and its Impact on Asthma (ARIA) classification. Group 1, mild intermittent symptoms; group 2, moderate-to-severe intermittent symptoms; group 3, mild persistent symptoms; and group 4, moderate-to-severe persistent symptoms. Values are represented as medians (black line), quartiles (25th and 75th percentiles, white box), and p values between the groups.](arh0041601870001){#F1}

DISCUSSION
==========

The main finding of our analysis was that the presence of an elevated level of sIgE was associated with the severity of AR. The impact of sIgE levels on symptom severity in patients with allergic airway disorders is still a matter of debate. Two pediatric studies were recently performed to directly address this topic. The first study was conducted on 186 children (ages, 2--12 years): 160 with perennial AR and 26 with non-AR as controls.^[@B12]^ On multiple linear regression analysis, the sIgE value was the independent predictor for symptom severity. Therefore, the researchers concluded that serum allergen sIgE may be considered a systemic marker for allergic inflammation and well correlated with the severity of nasal symptoms in children with perennial AR. The second study evaluated 107 children and adolescents with AR due to birch and grass pollen allergy.^[@B13]^ The researchers demonstrated that sIgE levels were associated with symptom severity during the pollen season. More recently, two studies investigated this topic in adult patients with AR.^[@B14],[@B15]^ Both studies demonstrated that the sIgE levels were associated with more-severe allergic symptoms. However, both studies considered the old AR classification. To give a response to the question whether serum sIgE may be related to symptom severity graded on the ARIA criteria, we performed this real-life study.

Our findings were not surprising because patients with moderate and severe persistent asthma shared the presence of elevated serum IgE levels. Previous evidence showed that high levels of IgE are associated with an increased prevalence of asthma, an increased airway hyperresponsiveness,^[@B16]--[@B19]^ and an accelerated decrease in lung function.^[@B20],[@B21]^ Our results may be clinically relevant in deciding whether patients are candidates for immunotherapy because high sIgE levels might identify patients with the best indication for such treatment. This would need to be evaluated with a study of the relationship between the sIgE level and symptom improvement with allergen immunotherapy. Moreover, the finding that an elevated level of sIgE was associated with severe symptoms in patients with persistent AR raised the possibility that sIgE could also be considered a prognostic factor of AR severity. This relationship should be investigated in a large longitudinal population study.

In the present study, some limitations should be acknowledged. There may be factors that influence the magnitude of the sIgE value, such as the number and/or density of IgE epitopes on a particular allergen, the affinity and/or avidity of IgE antibodies or the presence of sIgG antibodies. Furthermore, we could not exclude that SPT or a combination of SPT and sIgE may also be reliable biomarkers for symptom severity. In addition, it was discussed that a big trial on allergen immunotherapy included screening patients with positive SPT results but negative sIgE results,^[@B22],[@B23]^ which resulted in a dilution of the observed treatment effect of the investigational product and indicated that, in the setting of a clinical trial, a minimum level of allergen serum sIgE was important in identifying a population sufficiently symptomatic to enable evaluation of treatment benefit. In this regard, it was reported that patients with more-severe symptoms responded better to allergen immunotherapy than patients with milder symptoms.^[@B24]^ Our results were consistent with those of previous studies that demonstrated the high specificity of serum sIgE tests.^[@B25],[@B26]^ In addition, the relevance of biomarkers in AR management is an actual issue, as recently pointed out.^[@B27]^

CONCLUSION
==========

Our findings underlined the importance of sIgE as a feature of rhinitis. Not only because sIgE is a reliable biomarker of symptom severity in patients with persistent AR but also because it might help to assess the prognosis and influence decisions on treatment.
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